Long-term outcomes will determine the cost-effective approach to aortic valve disease

We appreciate the comments from Santarpino and colleagues regarding cost considerations in the treatment of severe aortic stenosis.1,2 Santarpino and colleagues observed a similar finding to our study in that the predominant cost difference associated with transcatheter aortic valve replacement (TAVR) remains the prosthesis. Presumably, over time many of these technology costs will decrease with increased competition or technologic advances in manufacturing costs.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Adult: Aortic valve: Letter to the editor Source Type: research